These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12219731)

  • 1. [Practice guidelines in gastroenterology. Use of anti-TNF agents in inflammatory bowel disease. European guide 2001-2003].
    Rom J Gastroenterol; 2002 Mar; 11(1):68-71. PubMed ID: 12219731
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF.
    Holtmann MH; Galle PR; Neurath MF
    Am J Gastroenterol; 2003 Feb; 98(2):504-5. PubMed ID: 12591081
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy of chronic inflammatory bowel diseases. TNF-alpha blocker in Crohn disease: earlier use is rewarding].
    MMW Fortschr Med; 2008 Dec; 150(51-52):54-5. PubMed ID: 19156959
    [No Abstract]   [Full Text] [Related]  

  • 4. [Selective TNF-alpha inhibition in Crohn disease. Emergency help in problem cases].
    MMW Fortschr Med; 2001 May; 143(18):52. PubMed ID: 11387713
    [No Abstract]   [Full Text] [Related]  

  • 5. [What can be expected from biological therapies for Crohn's disease?].
    Lemann M
    Gastroenterol Clin Biol; 2001 Nov; 25(11):945-7. PubMed ID: 11845043
    [No Abstract]   [Full Text] [Related]  

  • 6. [Biological compounds in the treatment of Crohn's disease].
    Dinari G
    Harefuah; 2001 Apr; 140(4):316-8. PubMed ID: 11303396
    [No Abstract]   [Full Text] [Related]  

  • 7. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment.
    Núñez Martínez O; Ripoll Noiseux C; Carneros Martín JA; González Lara V; Gregorio Marañón HG
    Am J Gastroenterol; 2001 May; 96(5):1665-6. PubMed ID: 11374737
    [No Abstract]   [Full Text] [Related]  

  • 8. [Infliximab--practical guidelines for the treatment of Crohn's disease].
    Bauerfeind P; Beglinger C; Beltinger J; Braegger C; Eigenmann F; Fried M; Guyot J; Hürlimann R; Michetti P; Seibold F; Straumann A
    Rev Med Suisse; 2006 Jul; 2(74):1807-15. PubMed ID: 16927560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balancing the risks and benefits of prolonged use of infliximab.
    Schölmerich J
    Gut; 2009 Apr; 58(4):477-8. PubMed ID: 19299379
    [No Abstract]   [Full Text] [Related]  

  • 10. Prediction of response to infliximab in Crohn's disease.
    Chaudhary R; Ghosh S
    Dig Liver Dis; 2005 Aug; 37(8):559-63. PubMed ID: 15893967
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [When can TNF-alpha inhibitors against inflammatory bowel disease be withdrawn?].
    Moum B
    Tidsskr Nor Laegeforen; 2007 Jun; 127(12):1673. PubMed ID: 17571118
    [No Abstract]   [Full Text] [Related]  

  • 13. Etanercept for Crohn's disease.
    Travers SB
    N Engl J Med; 2004 Feb; 350(8):840; author reply 840. PubMed ID: 14973205
    [No Abstract]   [Full Text] [Related]  

  • 14. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease.
    Beltrán B; Nos P; Bastida G; Iborra M; Hoyos M; Ponce J
    Gut; 2006 Nov; 55(11):1670-1. PubMed ID: 17047119
    [No Abstract]   [Full Text] [Related]  

  • 16. [When should anti-TNF-alpha treatment in Crohn disease be terminated?].
    Moum B
    Tidsskr Nor Laegeforen; 2010 Mar; 130(5):474. PubMed ID: 20224609
    [No Abstract]   [Full Text] [Related]  

  • 17. Drugs for inflammatory bowel disease.
    Treat Guidel Med Lett; 2009 Sep; 7(85):65-74; quiz 75-6. PubMed ID: 19696709
    [No Abstract]   [Full Text] [Related]  

  • 18. Inflixmab as a possible treatment for the hemorrhagic type of Crohn's disease.
    Tsujikawa T; Nezu R; Andoh A; Saotome T; Araki Y; Ishizuka Y; Sasaki M; Koyama S; Fujiyama Y
    J Gastroenterol; 2004; 39(3):284-7. PubMed ID: 15065007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour necrosis factor alpha antibody affects gastrin release in Crohn disease.
    Hopman WP; de Jong DJ; Naber AH; Jansen JB
    Scand J Gastroenterol; 2003 May; 38(5):522-5. PubMed ID: 12795463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of Crohn disease with anti-tumor necrosis factor alpha].
    Rasmussen SN; Petersen JA
    Ugeskr Laeger; 1999 Jun; 161(26):4026-9. PubMed ID: 10402946
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.